AKTS vs APMD: fair value comparison
Aktis Oncology, Inc. and Apnimed, Inc. · Updated 2026-10-19
AKTS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. APMD has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AKTS currently ranks higher by quality score.
| AKTS | APMD | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $15.06 | $17.76 |
| 12-month range | $15.06–$30.89 | $17.76–$26.85 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #174 of 301 Healthcare | #176 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Oversold |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: AKTS fair value analysis · APMD fair value analysis